Latest News

NovaBiotics Initiates Development of Orphan Drug in Cystic Fibrosis

17 December 2013

Formulation work commences for inhaled forms of Lynovex®.

NovaBiotics Ltd, the Aberdeen-based clinical-stage biotechnology company ("NovaBiotics" or the "Company"), today announced it has initiated the development of an inhaled form of Lynovex, its treatment for cystic fibrosis (CF).

Lynovex is an orphan drug candidate that breaks down mucus, disrupts and prevents bacterial films and acts as an antibacterial against Gram-negative and Gram-positive respiratory bacteria.

NovaBiotics is working with inhalation formulation specialists at Crystec in Bradford, UK to develop dry powder inhalable forms of the drug. The aim of administering the drug by aerosolisation is to deliver maximum efficiency with lower doses of the treatment targeted directly to the relevant areas of the respiratory tract.

As a maintenance therapy, the inhaled form of Lynovex is intended for the long term control of the chronic lung infections and mucus production associated with CF. In addition, NovaBiotics is investigating a tablet form for Lynovex for use in acute exacerbations of CF and is working with NHS Grampian and the University of Aberdeen's CF research team to undertake a phase IIa clinical trial of this new formulation, commencing in early 2014.

Dr Deborah O'Neil, CEO of NovaBiotics, said: "Current treatments for cystic fibrosis are limited and by no means wholly efficacious. Multiple therapies are often required but Lynovex could offer the possibility of a multifunctional, single treatment which addresses mucus production, bacterial infections and also persistent bacterial biofilms and I'm excited at the prospect of investigating how an inhaled form can achieve these clinical aims and, in doing so, could improve lung function in CF patients in the long term."

Peter York, Chief Scientist at Crystec, said: "We are delighted to be supporting NovaBiotics on this project. We believe that bringing together the therapeutic potential of Lynovex with the 'best in class' lung delivery performance of Crystec's engineered particles could represent a ground-breaking treatment for this debilitating disease."

As Lynovex progresses through clinical trials, NovaBiotics is enhancing its intellectual property and trademark portfolio for this and its other technologies and product candidates. NovaBiotics recently received a US grant for the Lynovex trademark.

NovaBiotics' collaboration with the Cystic Fibrosis Trust to fund the upcoming phase IIa study will be highlighted as a case study at the UK Bioindustry Association's Annual Parliament Day on 30 January 2014, a flagship advocacy event which represents the sector's top policy needs to senior policymakers across government and sets the agenda for the year ahead.

 

Older News

NovaBiotics secures an additional £3.0 million investment from Woodford Investment Management | 3rd March 2017
Commercial Collaboration Deal for (Oral) Lynovex® | 5th August 2016
NovaBiotics Announces New Data on Cysteamine (Nylexa™) as an Antimicrobial Resistance Breaker in Multi Drug Resistant Bacteria | 18 June 2016
NovaBiotics Highlights Importance of Co-ordinated Approach to Antimicrobial Resistance | 7th June 2016
NovaBiotics Wins Investment of the Year Award | 5 Feb 2016
Lynovex® Activity in CF sputum & Against the Emerging CF Pathogen, Mycobacterium abscessus | 12 Aug 2015
Phase IIa clinical study results for NovaBiotics' Lynovex® presented at the 38th Annual European Cystic Fibrosis Symposium | 12 Jun 2015
Launch of the BEAM Alliance | 9 Jun 2015
NovaBiotics Quoted in "What Investment" on 11 February | 11 Feb 2015
NovaBiotics Raises £5.0 million in a Private Placement from Woodford Investment Management | 19 Jan 2015
NovaBiotics' Dr Deborah O'Neil Named EY UK Health Products & Services Entrepreneur of 2014 | 7 Oct 2014
Showcases increasing investor interest in the global stem cell sector | 22 Sep 2014
NovaBiotics Receives Orphan Drug Status from the US Food and Drug Administration (FDA) for Lynovex® | 16 Sep 2014
Scotland's Pharmacells Group creates 12 new jobs at BioCity Scotland following acquisition by Precious Cells Group, London | 18 August 2014
Precious Cells Biobank Acquires Stem Cell Technology Leader Pharmacells Group | 25 July 2014
NovaBiotics' Dr Deborah O'Neil Wins Entrepreneur of the Year | 27 June 2014
NovaBiotics Initiates Phase IIa Clinical Study for Lynovex in Cystic Fibrosis | 25 June 2014
NovaBiotics' Dr Deborah O'Neil Named EY Scotland Entrepreneur of 2014 | 20 June 2014
NovaBiotics Initiates Development of Orphan Drug in Cystic Fibrosis | 17 December 2013
Pharmacells to expand following funding boost | 24 September 2013
NovaBiotics Enters into Agreement with Taro | 28 August 2013
First patient dosed at Aberdeen Royal Infirmary in major international study | 29 August 2012
Pharmacells in talks to extend reach overseas | 24 January 2012
New hope in cystic fibrosis fight as Scots patients first to test drug | 2 January 2012
NovaBiotics reveals plans for cystic fibrosis drug after EU grants orphan status | 19 December 2011
Pharmacells stores stem cells for teenager paralysed in car crash | 20 October 2011
NovaBiotics Ltd - Presentation at BIO International 2011, Washington DC | 24 June 2011
Launch of Oristem® | 04 June 2011
GBP in Nexxus newsletter, Spring 2011 | 22 March 2011
Patents granted in key territories as Novexatin® moves closer to further clinical development and commercialisation | 21 February 2011
Unblinded Phase IIa Clinical Trial Data Delivers Excellent Results for Novexatin®, Nova... | 5 July 2010
Successful Completion of Phase IIa clinical trial for Novexatin®, IND filing planned for Phase IIb... | 1 May 2010

Latest News

NovaBiotics secures an additional £3.0 million investment from Woodford Investment Management
3rd March 2017

Commercial Collaboration Deal for (Oral) Lynovex®
5th August 2016

NovaBiotics Announces New Data on Cysteamine (Nylexa™)
18th June 2016

NovaBiotics Highlights Importance of Co-ordinated Approach to Antimicrobial Resistance
7th June 2016

NovaBiotics Wins Investment of the Year Award
5th February 2016

Lynovex® Activity in CF sputum & Against the Emerging CF Pathogen, Mycobacterium abscessus
12th August 2015

Phase IIa clinical study results for NovaBiotics' Lynovex® presented at the 38th Annual European Cystic Fibrosis Symposium
12th June 2015

Launch of the BEAM Alliance
9th June 2015

NovaBiotics Quoted in "What Investment" on 11 February
11th February 2015

NovaBiotics Raises £5.0 million in a Private Placement from Woodford Investment Management
19th January 2015

NovaBiotics' Dr Deborah O'Neil Named EY UK Health Products & Services Entrepreneur of 2014
7th October 2014

Showcases increasing investor interest in the global stem cell sector
22nd September 2014

NovaBiotics Receives Orphan Drug Status from the US Food and Drug Administration (FDA) for Lynovex®
16th September 2014

Scotland's Pharmacells Group creates 12 new jobs at BioCity Scotland following acquisition by Precious Cells Group, London
18th August 2014

Precious Cells Biobank Acquires Stem Cell Technology Leader Pharmacells Group
25th July 2014